Patients with Primary Central Nervous System Lymphoma Not Eligible for Clinical Trials: Prognostic Factors, Treatment and Outcome

Sabine Seidel; Michelle Margold; Thomas Kowalski; Alexander Baraniskin; Roland Schroers; Agnieszka Korfel; Eckhard Thiel; Michael Weller; Peter Martus; Uwe Schlegel

doi:10.3390/cancers13122934

Cancers (Jun 2021)

Patients with Primary Central Nervous System Lymphoma Not Eligible for Clinical Trials: Prognostic Factors, Treatment and Outcome

Sabine Seidel,
Michelle Margold,
Thomas Kowalski,
Alexander Baraniskin,
Roland Schroers,
Agnieszka Korfel,
Eckhard Thiel,
Michael Weller,
Peter Martus,
Uwe Schlegel

Affiliations

Sabine Seidel: Department of Neurology, University Hospital Knappschaftskrankenhaus, Ruhr University Bochum, In der Schornau 23-25, D-44892 Bochum, Germany
Michelle Margold: Department of Neurology, University Hospital Knappschaftskrankenhaus, Ruhr University Bochum, In der Schornau 23-25, D-44892 Bochum, Germany
Thomas Kowalski: Department of Neurology, University Hospital Knappschaftskrankenhaus, Ruhr University Bochum, In der Schornau 23-25, D-44892 Bochum, Germany
Alexander Baraniskin: Department of Hematology and Oncology, University Hospital Knappschaftskrankenhaus, Ruhr University Bochum, In der Schornau 23-25, D-44892 Bochum, Germany
Roland Schroers: Department of Hematology and Oncology, University Hospital Knappschaftskrankenhaus, Ruhr University Bochum, In der Schornau 23-25, D-44892 Bochum, Germany
Agnieszka Korfel: Department of Hematology and Oncology, Charité Berlin, University of Berlin, Hindenburgdamm 30, D-12203 Berlin, Germany
Eckhard Thiel: Department of Hematology and Oncology, Charité Berlin, University of Berlin, Hindenburgdamm 30, D-12203 Berlin, Germany
Michael Weller: Department of Neurology, University Hospital and University of Zurich, Frauenklinikstrasse 26, CH-8091 Zürich, Switzerland
Peter Martus: Department of Biostatistics and Clinical Epidemiology, University of Tübingen, Silcherstr. 5, D-72076 Tübingen, Germany
Uwe Schlegel: Department of Neurology, University Hospital Knappschaftskrankenhaus, Ruhr University Bochum, In der Schornau 23-25, D-44892 Bochum, Germany

DOI: https://doi.org/10.3390/cancers13122934
Journal volume & issue: Vol. 13, no. 12
p. 2934

Abstract

Read online

Patients with primary central nervous system lymphoma (PCNSL) not fulfilling inclusion criteria for clinical trials represent an underreported population. Thirty-four consecutive PCNSL patients seen at our center between 2005 and 2019 with exclusion criteria for therapeutic trials were analyzed (non-study patients) and compared with patients from the G-PCNSL-SG-1 (German PCNSL Study Group 1) study (study patients), the largest prospective multicenter trial on PCNSL, comprising 551 patients. Median follow up was 68 months (range 1–141) in non-study patients and 51 months (1–105) in study patients. Twenty-seven/34 (79.4%) non-study patients received high dose methotrexate (HDMTX), while seven/34 (20.6%) with a glomerular filtration rate (GFR) p = 0.766). Favorable prognostic factors in non-study patients were young age, application of HDMTX and early response on magnet resonance imaging (MRI). If HDMTX-based chemotherapy can be applied, long-term disease control is possible even in patients not qualifying for clinical trials. Initial response on early MRI might be useful for decision on treatment continuation.

Published in Cancers

ISSN: 2072-6694 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.mdpi.com/journal/cancers/

About the journal

Abstract

Keywords